AGC Biologics, a CDMO expert, has partnered with Quell Therapeutics, a clinical-stage biotechnology company pioneering engineered T-regulatory (Treg) cell therapies, to support the development of multiple Treg cell therapy drug candidates targeting severe immune disorders. AGC Biologics will provide lentiviral vector (LVV) material using its proprietary ProntoLVV platform to prepare these therapies for CTA / IND submissions. Source: Contract Pharma 15/5/2025